Randomized trial develops hydrogels enhancing tissue regeneration in diabetic wounds, indicating therapeutic potential.
Chronic diabetic wounds remain a major clinical challenge because of persistent inflammation, excessive oxidative stress, impaired angiogenesis, and high susceptibility to infection. This study aims to develop a multifunctional hydrogel system composed of gelatin methacryloyl (GelMA; 7.5%, 10%, 15%), chitosan (2%), zeolite (1%), and glutathione (0.15 mg/mL) that can concurrently deliver antioxidant therapy, prevent infection, and support tissue regeneration in diabetic wounds. All GelMA/chitosan/zeolite/glutathione (Gel-CZG) hydrogels exhibited solid-like viscoelastic behavior and shear-thinning properties, with increasing GelMA concentration yielding higher stiffness. FTIR analysis confirmed the successful incorporation of glutathione, chitosan, and zeolite. SEM imaging revealed a highly interconnected porous microstructure, with pore size decreasing as GelMA concentration increased. Sustained glutathione release was achieved for up to 21 days, following a diffusion-controlled mechanism. The hydrogels were cytocompatible, supported fibroblast adhesion and proliferation, and modulated key inflammatory (e.g., IL-1β, TNF-α, IL-6, MMP13) and regenerative (e.g., IGF1, COL1A1) genes in a concentration-dependent manner. All formulations demonstrated > 90% antibacterial activity against E. coli, S. aureus, and P. aeruginosa and inhibited P. aeruginosa biofilm formation by ≥ 95%. Overall, the designed Gel-CZG hydrogels provide a robust and tunable platform that integrates sustained glutathione delivery, antibacterial action, and regenerative support.
No takes yet. Share an insight, caveat, or question.
Kabadas et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: